ASCO Gastrointestinal Cancer Symposium | Conference

Zev A. Wainberg, MD, on Future Research Efforts for Patients With Advanced Gastric Cancer
February 07, 2022

Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.

Ghassan K. Abou-Alfa, MD, on Integral Developments Leading to Phase 3 HIMALAYA Trial in Hepatocellular Carcinoma
February 05, 2022

Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.

CancerNetwork® Recaps Gong’s Twitter Takeover at ASCO GI 2022
January 31, 2022

Jun Gong, MD, hosted a Twitter takeover during the 2022 Gastrointestinal Cancers Symposium where he discussed breaking presentations in a #CNRealtimeReport.

Zev A. Wainberg, MD, Highlights the Rationale for Examining Long-Term Data From Pembrolizumab/Chemo in Advanced Gastric/GEJ Adenocarcinoma
January 29, 2022

Zev A. Wainberg, MD, spoke to the rationale for examining the efficacy of pembrolizumab alone and in combination with chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Ripretinib Does Not Meet Primary End Point vs Sunitinib for Pretreated GIST in Phase 3 INTRIGUE Study
January 25, 2022

Patients with pretreated gastrointestinal stromal tumors who were treated with ripretinib did not reach the primary end point of progression-free survival superiority vs sunitinib in the phase 3 INTRIGUE study.

Lenvatinib Yields Survival Benefit, Manageable Toxicities in Recurrent HCC After Liver Transplantation
January 24, 2022

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

Adding Nivolumab to SOC Fails to Extend PFS in Metastatic CRC
January 23, 2022

The CheckMate 9X8 trial did not hit the primary end point of progression-free survival superiority with nivolumab plus standard of care vs standard of care alone in metastatic colorectal cancer.

ctDNA Assays Identify Resectable CRC Likely to Benefit Adjuvant Chemotherapy
January 23, 2022

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Trastuzumab Deruxtecan Shows Encouraging Efficacy for HER2+ Metastatic Colorectal Cancer
January 23, 2022

Treatment with trastuzumab deruxtecan produced promising efficacy results for patients with HER2-positive metastatic colorectal cancer.

Encorafenib, Cetuximab, and Nivolumab Induced Responses and Was Tolerable in MSS, BRAFV600E-Mutated Metastatic CRC
January 22, 2022

Results from a phase 1/2 study showed that a combination of encorafenib, cetuximab, and nivolumab was well tolerated and yielded promising responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.